Kumar T K Susheel, Kashyap Pooja, Figueroa Mayte, Zurakowski David, Allen Jerry, Ballweg Jean A, Sathanandam Shyam, Ali Mohammed, Knott-Craig Christopher J
Department of Pediatric Cardiothoracic Surgery, Ann Arbor, MI, USA
Department of Pediatric Cardiology, Le Bonheur Children's Hospital and University of Tennessee, Memphis, TN, USA.
World J Pediatr Congenit Heart Surg. 2016 Jan;7(1):43-8. doi: 10.1177/2150135115614574.
Prolonged pleural effusion following Fontan operation is common and increases morbidity and hospital length of stay. Vasopressin (VP), a neurohypophysial hormone, has numerous effects on the cardiovascular system. The most notable is increased peripheral vascular resistance, but it may also reduce capillary leakage by tightening endothelial intercellular junctions and reducing capillary hydrostatic pressure We reviewed our experience with the perioperative administration of VP following Fontan operation.
We retrospectively reviewed the records of 62 consecutive patients who underwent Fontan operation from January 2004 to June 2014. In January 2010, VP was introduced as part of the standard perioperative management of patients undergoing Fontan operation at our center. For this retrospective observational study, patients were grouped according to the use (VP; N = 40) or nonuse (non-VP; N = 22) of VP (0.3-0.5 mU/kg/min) in the perioperative period. The primary end point analyzed was chest tube output. Secondary end points analyzed included fluid balance and length of hospital stay, with groups compared using Mann-Whitney U test.
There was no hospital mortality. Median total chest tube output was 22 mL/kg in the VP group and 68 mL/kg in the non-VP group (P < .001). The median total duration of chest tube indwelling time was five days in the VP group and was 11 days in the non-VP group (P < .001). Median fluid balance on first postoperative day was 13 and 38 mL/kg, respectively (P < .001). Median hospital stay for VP and non-VP groups was 9 and 16 days, respectively (P = .002).
The more recent group of patients undergoing Fontan operations, all of whom received VP perioperatively, had less chest tube output and shorter duration of chest tube drainage after the Fontan operation relative to the earlier patient group whose perioperative management did not include VP. They also experienced less positive fluid balance in the early postoperative period and shorter hospital length of stay than the patients from the earlier era.
Fontan手术后长期胸腔积液很常见,会增加发病率和住院时间。血管加压素(VP)是一种神经垂体激素,对心血管系统有多种作用。最显著的是增加外周血管阻力,但它也可能通过收紧内皮细胞间连接和降低毛细血管静水压来减少毛细血管渗漏。我们回顾了Fontan手术后围手术期使用VP的经验。
我们回顾性分析了2004年1月至2014年6月连续62例行Fontan手术患者的记录。2010年1月,VP被引入作为我们中心Fontan手术患者围手术期标准管理的一部分。对于这项回顾性观察研究,患者根据围手术期是否使用VP(0.3 - 0.5 mU/kg/min)分为使用组(VP组;N = 40)或未使用组(非VP组;N = 22)。分析的主要终点是胸管引流量。分析的次要终点包括液体平衡和住院时间,组间比较采用Mann-Whitney U检验。
无住院死亡病例。VP组胸管总引流量中位数为22 mL/kg,非VP组为68 mL/kg(P < 0.001)。VP组胸管留置总时间中位数为5天,非VP组为11天(P < 0.001)。术后第一天液体平衡中位数分别为13和38 mL/kg(P < 0.001)。VP组和非VP组住院时间中位数分别为9天和16天(P = 0.002)。
与围手术期管理未包括VP的早期患者组相比,近期接受Fontan手术的患者组,所有患者围手术期均接受VP治疗,Fontan手术后胸管引流量更少,胸管引流持续时间更短。他们术后早期的液体正平衡也比早期患者少,住院时间更短。